Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Needham & Company LLC

Needham & Company LLC started coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 317.36% from the stock’s current price.

STTK has been the subject of several other research reports. Citigroup boosted their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Wedbush lifted their price target on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research note on Friday. TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Finally, Piper Sandler began coverage on Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Shattuck Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $5.99 on Friday. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $6.00. The company has a market capitalization of $379.05 million, a price-to-earnings ratio of -7.78 and a beta of 1.55. The business has a 50-day moving average of $4.17 and a 200-day moving average of $2.84.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to analyst estimates of $0.17 million. Research analysts expect that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Trading of Shattuck Labs

Several hedge funds have recently made changes to their positions in STTK. T. Rowe Price Investment Management Inc. bought a new position in Shattuck Labs during the 4th quarter worth $4,945,000. Invesco Ltd. bought a new position in shares of Shattuck Labs during the fourth quarter worth about $103,000. EP Wealth Advisors LLC bought a new position in shares of Shattuck Labs during the fourth quarter worth about $150,000. Sphera Funds Management LTD. acquired a new stake in shares of Shattuck Labs in the 4th quarter worth about $713,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Shattuck Labs in the 4th quarter worth about $7,031,000. Institutional investors own 58.74% of the company’s stock.

Key Stories Impacting Shattuck Labs

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Needham & Company initiated coverage with a “Buy” and a $25.00 price target, implying a very large upside potential vs. the current price; this is a major bullish catalyst for investor interest. Needham coverage
• Positive Sentiment: Wedbush raised its price target from $4.00 to $8.00 and kept an “Outperform” rating — a supportive signal from another sell‑side shop that likely contributed to the intraday move. Wedbush note
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating and a $6.00 price target while publishing detailed quarterly and multi‑year EPS forecasts for 2026–2028; the reiteration provides some analyst-level support but with a much lower target than Needham. HC Wainwright coverage
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across FY‑2026 to FY‑2028 (FY‑2026: now ($0.83) from ($0.71); FY‑2027: now ($0.88) from ($0.76); FY‑2028: now ($1.04) from ($0.90)) and issued quarterly EPS projections for 2026 (Q1 ($0.18), Q2 ($0.19), Q3 ($0.22), Q4 ($0.24)). Those cuts signal weaker near‑term profitability expectations and are a negative for fundamentals despite the maintained Buy rating.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.